Enliven Therapeutics Inc. (ELVN) Live Share Price, Invest From India

Enliven Therapeutics Inc. Stock Performance

as on May 1, 2026 at 6:59 am IST

Day's Low
Day's High
$40.69
Day's Price Range
$43.49
$41.24
1.33%
Downside
5.46%
Upside
52 Week's Low
52 Week's High
$14.79
52-Week Price Range
$48.53
$41.24
64.15%
Downside
17.68%
Upside

Enliven Therapeutics Inc. share price movements today

Previous Close: $42.40
Open: $43.02
Volume: 748.2K
Day's Low - High: $40.69 - $43.49
52 Week Low - High: $14.79 - $48.53

Enliven Therapeutics Inc. Historical Returns

1 Month Return: + 15.88 %
3 Month Return: + 60.3 %
1 Year Return: + 123.86 %
3 Year Return: + 122.69 %
5 Year Return: 0 %

Enliven Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Enliven Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.6B

EPS (TTM)

-1.94

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-119.4M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-26.95%

Enliven Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Enliven Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Enliven Therapeutics Inc.	BUY	$2.6B	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.2B	114.16%	129.82	8.45%
Vertex Pharmaceuticals Inc	BUY	$109.4B	93.97%	28.1	32.94%
BeiGene, Ltd.	NA	$32.3B	NA	117.73	5.37%
Regeneron Pharmaceuticals Inc	BUY	$76.7B	42.61%	17.64	31.41%

Stock Returns calculator for Enliven Therapeutics Inc. Stock including INR - Dollar returns

The Enliven Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Enliven Therapeutics Inc. investment value today

Current value as on today

₹2,44,280

Returns

₹1,44,280

(+144.28%)

Returns from Enliven Therapeutics Inc. Stock

₹1,17,740 (+117.74%)

Dollar Impact

₹26,540 (+26.54%)

Analyst Recommendation on Enliven Therapeutics Inc. Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Enliven Therapeutics Inc.. Average target price of $51.29

Enliven Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Enliven Therapeutics Inc..

What analysts predicted

19.59%UPSIDE

Target Price

$51.29

Current Price

$41.24

Analyzed by

10 Analysts

Target

$51.29

Enliven Therapeutics Inc. target price $51.29, a slight upside of 19.59% compared to current price of $41.24. According to 10 analysts rating.

Enliven Therapeutics Inc. Stock’s Investor Sentiment and Interest

Search interest for Enliven Therapeutics Inc. Stock has increased by 140% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 1, 2026 to May 1, 2026

Change:140% versus previous 30 day period

Enliven Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	0	-	-	-	0	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	-	0
Operating Income	-24	-22	-25	-24	-27	-26	-31	-28	-25	-34
EBITDA	-24	-22	-25	-24	-26	-26	-31	-28	-20	-34
Interest Expense	-	1	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-20	-19	-22	-19	-23	-23	-28	-25	-20	-29
Income Tax Expense	-3	5	0	0	-	0	-	-	-	-
Net Income	-20	-19	-22	-19	-23	-23	-28	-25	-20	-29
Net Profit Margin	0.00%	-4402.27%	0.00%	0.00%	0.00%	-7335.44%	0.00%	0.00%	0.00%	0.00%

Enliven Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0
Operating Income	-9	-24	-38	-83	-104	-119
EBITDA	-9	-24	-38	-83	-104	-119
Interest Expense	-	0	1	-	-	-
Depreciation	0	0	0	0	0	0
Income Before Tax	-18	-24	-37	-71	-88	-103
Income Tax Expense	0	0	0	1	0	-
Net Income	-18	-24	-37	-71	-89	-103
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Enliven Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-19	-22	-19	-23	-23	-28	-25	-20	-29
Operating Cash Flow	-12	-23	-20	-12	-17	-24	-17	-13	-15
Investing Cash Flow	38	-17	-33	14	0	1	-183	-4	12
Financing Cash Flow	0	90	1	1	39	0	218	0	0
Change in Cash	26	49	-52	3	23	-22	17	-17	-2

Enliven Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-11	-23	-18	-24	-37	-71	-89	-103
Operating Cash Flow	-8	-21	-8	-19	-32	-61	-73	-70
Investing Cash Flow	-	-24	0	0	0	-148	-35	-173
Financing Cash Flow	6	43	130	-1	-1	234	133	218
Change in Cash	-2	-2	121	-20	-34	24	23	-25

Enliven Therapeutics Inc. News & Key Events

Insights on Enliven Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ELVN has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 3 months, ELVN stock has moved up by 60.3%
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ELVN has outperformed top 5 stocks with highest market-cap in its industry

About Enliven Therapeutics Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Organisation	Enliven Therapeutics Inc.
Headquarters	6200 Lookout Road, Boulder, CO, United States, 80301
Industry	Biotechnology
CEO	Dr. Joseph P. Lyssikatos Ph.D.
E-voting on shares	Click here to vote

Key Management of Enliven Therapeutics Inc.

Name	Title
Dr. Joseph P. Lyssikatos Ph.D.	Co-Founder & Chief Scientific Officer
Dr. Helen Louise Collins M.D.	Chief Medical Officer
Mr. Anish Patel Pharm.D.	Co-Founder & COO
Dr. Galya D. Blachman Esq., Ph.D.	Chief Legal Officer & Head of Business Development

FAQs

What is Enliven Therapeutics Inc. share price today?

Enliven Therapeutics Inc. share price today is $41.24 as on May 1, 2026 at 1:29 am IST at the close of the market. Enliven Therapeutics Inc. share today touched a day high of $43.49 and a low of $40.69.

What is the 52 week high and 52 week low for Enliven Therapeutics Inc. share?

Enliven Therapeutics Inc. share touched a 52 week high of $48.53 on April 17, 2026 and a 52 week low of $14.79 on January 6, 2026. Enliven Therapeutics Inc. stock price today i.e. May 1, 2026 at 1:29 am IST is closed at $41.24,which is 15.02% down from its 52 week high and 178.93% up from its 52 week low.

What is Enliven Therapeutics Inc.'s market capitalisation today?

Enliven Therapeutics Inc. market capitalisation is $0.00T as on May 1, 2026 at 1:29 am IST.

How to invest in Enliven Therapeutics Inc. Stock (ELVN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Enliven Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enliven Therapeutics Inc. Shares that will get you 0.0364 shares as per Enliven Therapeutics Inc. share price of $41.24 per share as on May 1, 2026 at 1:29 am IST.

What is the minimum amount required to buy Enliven Therapeutics Inc. Stock (ELVN) from India?

Indian investors can start investing in Enliven Therapeutics Inc. (ELVN) shares with as little as ₹94.91 or $1 (as of May 1, 2026 at 4:51 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in Enliven Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on May 1, 2026 at 4:51 am IST). Based on Enliven Therapeutics Inc. share’s latest price of $41.24 as on May 1, 2026 at 1:29 am IST, you will get 0.2425 shares of Enliven Therapeutics Inc.. Learn more about fractional shares .